Results 41 to 50 of about 79,249 (245)

Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report

Clinical Medicine Insights: Case Reports, 2023
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun, Hsien-Yung Lai, Yi-Ting Chuang, Hsuen-Fu Lin   +3 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice

Pharmaceuticals, 2020
Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa, Deiziane V. S. Costa, Caren N. S. Sousa, Angeline M. H. P. Silva, Ingridy S. Medeiros, Dainesy S. Martins, Conceição S. Martins, Ana L. V. Pequeno, Roberto C. P. Lima-Júnior, Pedro M. G. Soares, Silvânia M. M. Vasconcelos, Gerly A. C. Brito, Emmanuel P. Souza   +12 more
doaj   +1 more source

Effect of echinacoside as a palliative for irinotecan-induced intestinal mucositis

Интегративная физиология, 2023
Irinotecan, an anticancer drug, causes severe delayed diarrhea due to its active metabolite, SN-38, which damages the intestinal mucosa. This diarrhea may lead to the discontinuation of anticancer therapy in clinical practice.
Хикару Оцуки, Шизука Джонан, Тайсэй Цудзии, Нахла Хамуда, Кикуко Амагазе   +4 more
doaj   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Therapeutic Advances in Medical Oncology, 2020
Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or ...
Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara   +14 more
doaj   +1 more source

Impact of omega 3 alone or in combination with irinotecan on bone marrow and spleen of rats: in vivo study

Iraqi Journal of Pharmaceutical Sciences, 2023
Objectives: The present study designed to explore the genotoxicity through measurement of Mitotic index in bone marrow and the spleen cells, as possible mechanism of bone marrow and spleen toxicity that induced by irinotecan; and to describe the ...
Alaa Radhi, Nada Al-Shawi, Ali Hassan
doaj   +1 more source

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]

, 2016
Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F., Danesi, R., De Gregorio, V., Falcone, A., Fornaro, L., Graziano, F., Loupakis, F., Masi, G., Paolicchi, E., Ricci, V., Ronzoni, M., Vivaldi, C.   +11 more
core   +1 more source

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio‐Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez, Anna Felip‐Badia, Marina Caballero‐Bellon, Nazaret Sanchez‐Sierra, Alicia Castañeda, Moira Garraus, Maite Gorostegui, Margarida Simão‐Rafael, Juan Pablo Muñoz, Marta Perez‐Somarriba, Salvador Mañe, Mariana Cecilia Planells, Sara Perez‐Jaume, Jaume Mora   +13 more
wiley   +1 more source